Gramercy Funds Management LLC Names Emerging Markets Expert Hamad Almudhaf as Managing Director, Head of International Capital Markets
Gramercy Funds Management LLC (“Gramercy”), a $6 billion, global emerging markets investment manager, today announced that Hamad Almudhaf has joined the firm in a newly created role, Head of International Capital Markets. Mr. Almudhaf will be responsible for the design and implementation of Gramercy’s international expansion strategy to further enhance the firm’s high quality investor relationships outside of the U.S. He will also have a principal responsibility for the continued development of Gramercy’s international, commercial and capital formation strategy.
“We are thrilled to have Hamad join the Gramercy team in this critically important new role,” said Robert Koenigsberger, Managing Partner and Chief Investment Officer of Gramercy. “Over the last 25 years, Gramercy has successfully established the firm as a prominent global emerging markets investment management company. Hamad’s proven track record of success will further advance our leading position in emerging markets and private credit, and ensure we deliver on our core mission while providing clients with a better approach to emerging markets.”
“We are delighted that Hamad is joining Gramercy,” said Mohamed El-Erian, Chair of Gramercy. “His expertise, experience and accomplishments are not just important supplements to the firm’s resources but also enablers of its further success. We look forward to having him on our team.”
Mr. Almudhaf has over fifteen years of financial markets experience in investment banking and international capital markets and has established a diverse set of important global investor relationships. More recently, Mr. Almudhaf has worked closely with the Gramercy investment team, sourcing and structuring unique investment opportunities while in his senior role at J.P. Morgan’s fixed income franchise in New York City. Prior to J.P. Morgan, Mr. Almudhaf began his investment banking career with Itaú Unibanco, specializing in fixed income credit markets and special situations investments in Latin America. In his new capacity, Mr. Almudhaf will be based in Gramercy’s headquarters in Greenwich, Connecticut and responsible for shaping the firm’s international goals and objectives for growth and expansion.
“We are pleased to announce that Hamad has joined Gramercy,” said Tom Humphrey, President and Senior Partner of Gramercy. “Hamad is extremely well regarded and an experienced global markets professional. His technical expertise, cross-regional experience, and commercial skills will be immediately additive for Gramercy worldwide.”
“I have been working closely with the Gramercy team for many years,” said Mr. Almudhaf. “I am excited to join a team of highly respected, skilled and dedicated global emerging markets professionals. Gramercy’s rigorous investment process creates unique opportunities for clients to deploy capital and I’m looking forward to originating high quality investment solutions across international capital markets.”
Mr. Almudhaf graduated Magna Cum Laude from the Wharton School of the University of Pennsylvania, holding a Bachelor of Science degree in Economics with a triple Concentration in Finance, Strategic Management and Legal Studies & Business Ethics. Mr. Almudhaf is a CFA® charterholder.
About Gramercy:
Gramercy is a global emerging markets investment manager based in Greenwich, Connecticut with offices in London, Buenos Aires, Miami, West Palm Beach and Mexico City, and dedicated lending platforms in Mexico, Turkey, Peru, Pan-Africa, Brazil, and Colombia. The $6-plus billion firm, founded in 1998, seeks to provide investors with a better approach to emerging markets, delivering attractive risk-adjusted returns supported by a transparent and robust institutional platform. Gramercy offers alternative and long-only strategies across emerging markets asset classes, including multi-asset, private credit, public credit, and special situations. Gramercy’s mission is to positively impact the well-being of our clients, portfolio investments and team members. Gramercy is a Registered Investment Adviser with the US Securities and Exchange Commission (SEC), a Signatory of the Principles for Responsible Investment (PRI), a Signatory to the Net Zero Asset Managers initiative (NZAMI) and a Supporter of the Task Force on Climate-Related Financial Disclosures (TCFD). Gramercy Ltd, an affiliate, is registered with the UK Financial Conduct Authority (FCA). www.gramercy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319963926/en/
Contact information
Investors:
Lacie Smith
Gramercy
203-552-1928
lsmith@gramercy.com
Media:
Steve Bruce | Keely Gispan
ASC Advisors
203-992-1230
sbruce@ascadvisors.com | kgispan@ascadvisors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 18:00:00 EEST | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm
Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 01:40:00 EEST | Press release
Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing
Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 21:46:00 EEST | Press release
Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s
Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 17:20:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 13:00:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom